home / stock / zfgn / zfgn news


ZFGN News and Press, Zafgen

Stock Information

Company Name: Zafgen
Stock Symbol: ZFGN
Market: NASDAQ

Menu

ZFGN ZFGN Quote ZFGN Short ZFGN News ZFGN Articles ZFGN Message Board
Get ZFGN Alerts

News, Short Squeeze, Breakout and More Instantly...

ZFGN - Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chi...

ZFGN - TGI, ABIO, HPQ and LK among midday movers

 Gainers:  ARCA biopharma (NASDAQ: ABIO )  +174% . More news on: ARCA biopharma, Inc., Monaker Group, Inc., Triumph Group, Inc., Stocks on the move, , Read more ...

ZFGN - TWTR, HPQ among premarket losers

Greenpro Capital (NASDAQ: GRNQ ) -24% . More news on: Greenpro Capital Corp., Euroseas Ltd., Zafgen, Inc., Stocks on the move, , Read more ...

ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

ZFGN - Zafgen to merge with Chondrial Therapeutics; shares up 21% premarket

Zafgen (NASDAQ: ZFGN ) is up  21%  on entering into a definitive merger agreement with Chondrial Therapeutics under which Chondrial will become a wholly-owned subsidiary of Zafgen. More news on: Zafgen, Inc., Healthcare stocks news, Stocks on the move, Read more ...

ZFGN - Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for Friedreich’s ataxia  Companies to host confere...

ZFGN - Zafgen reports Q3 results

Zafgen (NASDAQ: ZFGN ): Q3 GAAP EPS of -$0.35. More news on: Zafgen, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ZFGN - Zafgen Reports Third Quarter 2019 Financial Results

Evaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results. In September 2019, Zafgen announced plans to explore strategic options to maximize shareholder value and the...

ZFGN - Cantor likes Durect in premarket analyst action

Durect (NASDAQ: DRRX ) initiated with Overweight rating and $5 (201% upside) price target at Cantor Fitzgerald. More news on: DURECT Corporation, Ekso Bionics Holdings, Inc., Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

ZFGN - Zafgen to explore strategic alternatives

Aimed at boosting shareholder value, Zafgen (NASDAQ: ZFGN ) will explore strategic alternatives that could include a merger, business combination or in-licensing. More news on: Zafgen, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Next 10